Stephen Harrap Selected Research

Vascular Diseases (Vascular Disease)

2/2022	Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes.
1/2022	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE.
1/2021	The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial.
1/2021	History of lower-limb complications and risk of cancer death in people with type 2 diabetes.
1/2021	Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial.
12/2020	Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.
1/2020	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study.
1/2020	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
1/2020	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial.
11/2019	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen Harrap Research Topics

Disease

37	Vascular Diseases (Vascular Disease) 02/2022 - 04/2009
35	Type 2 Diabetes Mellitus (MODY) 02/2022 - 06/2008
7	Hypertension (High Blood Pressure) 01/2022 - 03/2011
5	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 03/2014
4	Stroke (Strokes) 11/2021 - 01/2017
3	Genetic Risk Score 01/2022 - 01/2021
2	Dementia (Dementias) 11/2021 - 01/2021
2	Diabetes Complications 10/2021 - 01/2021
2	Kidney Diseases (Kidney Disease) 02/2021 - 05/2016
2	Diabetes Mellitus 01/2019 - 01/2019
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2014 - 03/2011
1	Transient Ischemic Attack 11/2021
1	Cognitive Dysfunction 11/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 02/2021
1	Necrosis 02/2021
1	Frailty 01/2021
1	Retinal Diseases 01/2021
1	Obesity 12/2020
1	Hypoglycemia (Reactive Hypoglycemia) 01/2020
1	Myocardial Infarction 01/2019
1	Hypotension (Low Blood Pressure) 01/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 05/2016
1	Blindness (Hysterical Blindness) 01/2016
1	Inflammation (Inflammations) 03/2014
1	Coronary Disease (Coronary Heart Disease) 05/2013
1	Weight Loss (Weight Reduction) 05/2013
1	Essential Hypertension 02/2012
1	Coronary Artery Disease (Coronary Atherosclerosis) 03/2011

Drug/Important Bio-Agent (IBA)

37	Gliclazide (Diamicron)IBA 02/2022 - 06/2008
35	perindopril drug combination indapamideIBA 02/2022 - 04/2009
14	Perindopril FDA LinkGeneric 01/2022 - 04/2009
14	Glucose (Dextrose)FDA LinkGeneric 10/2021 - 06/2008
11	Indapamide FDA LinkGeneric 01/2022 - 04/2009
5	Biomarkers (Surrogate Marker)IBA 02/2021 - 03/2014
3	Antihypertensive Agents (Antihypertensives)IBA 02/2022 - 03/2011
3	CreatinineIBA 01/2021 - 01/2019
2	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2021
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2020
2	Biological ProductsIBA 01/2022 - 02/2012
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 03/2011
2	Retinaldehyde (Retinal)IBA 10/2016 - 01/2016
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2014 - 06/2008
1	Pharmaceutical PreparationsIBA 01/2022
1	Apolipoproteins E (ApoE)IBA 11/2021
1	Type II Tumor Necrosis Factor ReceptorsIBA 02/2021
1	AntibodiesIBA 02/2021
1	Neoplasm AntibodiesIBA 02/2021
1	AutoantibodiesIBA 02/2021
1	Type I Tumor Necrosis Factor ReceptorsIBA 02/2021
1	Bone Morphogenetic Protein 7IBA 02/2021
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 02/2021
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 02/2021
1	CholesterolIBA 01/2021
1	AlbuminsIBA 01/2021
1	ORALIT (ORS)IBA 01/2021
1	Cystatin CIBA 12/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020
1	1,5-anhydroglucitolIBA 01/2019
1	Polymethyl Methacrylate (Sol)IBA 01/2019
1	NucleotidesIBA 01/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019
1	omega-Chloroacetophenone (Mace)IBA 01/2017
1	Ephrin-B3 (Ephrin B3)IBA 01/2017
1	3' Untranslated Regions (3' UTR)IBA 01/2017
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2016
1	MMEIBA 12/2015
1	Fibroblast Growth Factor 1 (FGF-1)IBA 12/2015
1	Troponin T (Troponin T1)IBA 08/2014
1	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2014
1	pro-brain natriuretic peptide (1-76)IBA 08/2014
1	Fibrinogen (Factor I)FDA Link 03/2014
1	Interleukin-6 (Interleukin 6)IBA 03/2014
1	C-Reactive ProteinIBA 03/2014
1	Dietary SodiumIBA 02/2014
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 02/2014
1	SaltsIBA 05/2013
1	Nitric Oxide Synthase (NO Synthase)IBA 02/2012
1	BradykininIBA 03/2011
1	AngiotensinogenIBA 03/2011
1	Kallikreins (Kallikrein)IBA 03/2011
1	Prorenin ReceptorIBA 03/2011
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 03/2011

Therapy/Procedure

8	Therapeutics 01/2021 - 03/2011
3	Glycemic Control 01/2020 - 06/2008
2	Light Coagulation 10/2016 - 01/2016
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2019
1	Kidney Transplantation 05/2016
1	Surgical Amputation (Amputations) 01/2016